GZ 402668

Drug Profile

GZ 402668

Alternative Names: GLD 52; GZ402668

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Monoclonal antibodies
  • Mechanism of Action CD52 antigen modulators; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 22 Apr 2017 Pharmacodynamics and safety data from a phase Ib trial in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAAN-217)
  • 01 Dec 2016 Sanofi initiates enrolment in a phase I trial for Multiple sclerosis in Germany (SC) (NCT02977533)
  • 28 Nov 2016 Sanofi plans a phase I trial for Multiple sclerosis in Germany (SC) (NCT02977533)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top